MedTrace Logo

Drip-infusion of Remifentanil for RIH

NCT04387097 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 559

Last updated 2020-05-15

No results posted yet for this study

Summary

The development of remifentanil-induced hyperalgesia (RIH) is an unpleasant experience for surgical patients. An alternative management, gradual withdrawal of remifentanil was effective in prevention of RIH. The investigators designed a simple modality to assess if under withdrawal of remifentanil and further drip-infusion of remifentanil immediately after extubation affected postoperative pain score, the requirement of rescue analgesics, and adverse effects.

Conditions

  • Hyperalgesia

Interventions

DRUG

remifentanil

postoperative drip-infusion of remifentanil

Sponsors & Collaborators

  • Tri-Service General Hospital

    lead OTHER

Principal Investigators

  • Yi-hsuan Huang, MD · Tri-Service General Hospital and National Defense Medical Center

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-01
Primary Completion
2019-01-31
Completion
2019-07-22

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04387097 on ClinicalTrials.gov